- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02394080
Safety and Efficacy Study of the Treatment of Humerus Fractures
CE Marking Study of the IlluminOss Photodynamic Bone Stabilization System for the Treatment of Humerus Fractures
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Cologne, Germany, D-50733
- St. Vinzenz-Hospital GmbH
-
Gummersbach, Germany, 51643
- Klinikum Oberberg GmbH
-
Wetzlar, Germany, 35578
- Lahn-Dill Kliniken
-
-
-
-
-
Breda, Netherlands, 4818 CK
- Amphia Hospital
-
Dordrecht, Netherlands, 3318 AT
- Albert Schweitzer Hospital
-
Maastricht, Netherlands, 6229 HX
- University Hospital Maastricht
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Fracture-Specific Inclusion Criteria
- Radiograph-confirmed diagnosis of acute, single isolated fracture of the humerus. AO classification 11A2, 11A3 and 11B1, 11B2 and 12A1, 12A2, 12A3 and 12B1, 12B2 (The Netherlands); AO Classification 11A1, 11A2, 11A3 and 11B1, 11B2 and 12A1, 12A2, 12A3 and 12B1, 12B2 and 13A1, 13A2 and 13B1, 13B2 (Germany).
Fracture is closed, Gustilo Type I or II.
General Inclusion Criteria
- Skeletally mature men and women, 50 years of age or older (The Netherlands only) or 61 years of age or older (Germany only) at time of index injury.
a) Female patients of child bearing potential agree to use double barrier method of contraception (The Netherlands only) b) Female patients of non-child bearing potential must meet one of the following criteria (The Netherlands only):
- Postmenopausal for at least 1 year, or
- Documented oophorectomy or hysterectomy, or
- Surgically sterile
- Willing and able to understand and sign the informed consent.
Fracture-Specific Exclusion Criteria
- Index treatment is greater than 28 days (The Netherlands only) or 14 days (Germany only) post fracture
- Open fractures with severe contamination.
- Extremely comminuted fractures where insufficient holding power of the balloon on the intramedullary canal is probable.
- Marked bone loss or bone resorption patients, who due to a prior delayed union or non-union of the bones or other illnesses, may not be able to have their fracture adequately reduced prior to placement of the IlluminOss-device. This could leave bone void spaces that would preclude the device from maintaining alignment of the fractured bone.
Previous fracture of affected limb.
General Exclusion Criteria
- Pregnant or lactating (The Netherlands only).
- Patients with a contralateral fracture of the forearm or humerus (Germany only).
- Active or incompletely treated infections that could involve the site where the device will be implanted.
- Distant foci of infections that may spread to the implant site
- Uncooperative patients or patients, who are incapable of following directions (for example as a consequence of a neurological or psychiatric disorder).
- Concomitant metabolic disorders that may impair bone formation.
- Osteomalacia.
- Allergic to implant materials or dental glue.
- Vascular insufficiency, muscular atrophy, or neuro-muscular disease.
- Polytrauma patients (multiple injuries resulting from a high-impact event, eg- a motor vehicle accident).
- Life expectancy less than one year due to concurrent illness.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Photodynamic Bone Stabilization System (PBSS)
The PBSS is comprised of an inflatable, thin walled polyethylene terephthalate (PET; Dacron™) balloon mounted on an insertion catheter.
This balloon catheter system is designed to deliver the monomer cement to the fracture site via the medullary canal of the bone.
|
Treatment of acute humerus fractures
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Normal Radiographic Fracture Healing
Time Frame: 180 days
|
Two of four cortices or two of four views demonstrating bridging on standard radiographs
|
180 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation of Complete Radiographic Healing
Time Frame: 180 and 360 days
|
Three of four cortices or three of four views demonstrating bridging, with dissolution of the majority (greater than or equal to 75% on orthogonal views) of fracture lines
|
180 and 360 days
|
|
Evaluation of Normal Radiographic Healing
Time Frame: 360 days
|
Two of four cortices or two of four views demonstrating bridging on standard radiographs
|
360 days
|
|
Summary of Pain VAS
Time Frame: 180 and 360 days
|
Change from baseline of pain visual analog score (VAS).
Participants indicate their pain level by marking a point along a continuous horizontal line anchored by "No Pain" and "Severe Pain.
Total score range: 0 to 100 units on a scale 0 = No pain 100 = Severe pain.
Lower scores represent a better outcome (less pain), while higher scores represent a worse outcome (greater pain)
|
180 and 360 days
|
|
Summary of DASH Score
Time Frame: 180 and 360 days
|
Change from baseline of disability of the arm shoulder and hand (DASH) score.
DASH Disability/Symptom Total Score range: 0 to 100 units on a scale 0 = No disability/symptoms; 100 = Most severe disability/symptoms.
Each item is scored on a 5-point Likert scale.
Lower scores represent a better outcome (less disability and fewer symptoms), while higher scores represent a worse outcome (greater disability and more severe symptoms)
|
180 and 360 days
|
|
Summary of Constant Shoulder Score
Time Frame: 180 and 360 days
|
Change from baseline of constant shoulder score.
Total Constant Score range: 0 to 100 units on a scale 0 = Worst shoulder function; 100 = Best shoulder function.
The total Constant Score is calculated by summing the four subscale scores for a maximum of 100 points.
Higher scores represent a better outcome (improved shoulder function and less pain), while lower scores represent a worse outcome (greater disability and impaired shoulder function).
|
180 and 360 days
|
|
Summary of Pain on Palpation
Time Frame: 180 and 360 days
|
Pain at Palpation (yes/no), grade and clinical significance.
Grade: mild, moderate, severe
|
180 and 360 days
|
|
Summary of Return to Pre-Fracture Mobility
Time Frame: 180 and 360 days
|
Summary of subjects who returned to pre-fracture mobility (yes/no)
|
180 and 360 days
|
|
Summary of Range of Motion
Time Frame: 180 and 360 days
|
Summary of range of motion (active and passive) for affected and unaffected arm, for abduction, flexion, extension and lateral and medial rotation.
|
180 and 360 days
|
|
Summary of Disability Status
Time Frame: 180 and 360 days
|
Disability status as determined by the investigator
|
180 and 360 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 12-03-EUHUM-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Humerus Fractures
-
Baylor College of MedicineWithdrawnSupracondylar Humerus FracturesUnited States
-
Federal University of São PauloUnknownHumerus Fracture | Fracture of Shaft of HumerusBrazil
-
KK Women's and Children's HospitalRecruitingSupracondylar Humerus FractureSingapore
-
Royal Devon and Exeter NHS Foundation TrustNot yet recruitingDistal Humerus FractureUnited Kingdom
-
University of Massachusetts, WorcesterNot yet recruiting
-
Tan Tock Seng HospitalRecruitingProximal Humerus FracturesSingapore
-
Ain Shams UniversityCompletedProximal Humerus FracturesEgypt
-
Assistance Publique - Hôpitaux de ParisCompletedProximal Humerus FracturesFrance
-
Kahramanmaras Sutcu Imam UniversityUnknownHumerus Fracture
-
Technische Universität DresdenActive, not recruitingProximal Humerus FractureGermany
Clinical Trials on Photodynamic Bone Stabilization System
-
IlluminOss Medical, Inc.TerminatedHumerus Pathological FractureAustria, Germany, Netherlands
-
IlluminOss Medical, Inc.CompletedHumerus Fracture Metastatic Bone DiseaseUnited States
-
Superior UniversityActive, not recruiting
-
University of ChileCompletedDental Implants | Maxillary Alveolar Reconstruction | Dental Implants , Osseointegration , Marginal Bone Loss , Implant StabilityChile
-
Paradigm SpineMCRATerminatedSpondylolisthesis | Kyphosis | Neurologic Deficits | PseudarthrosisUnited States
-
University of CalgaryCanadian Orthopaedic Foundation; Calgary Orthopaedic Research and Education... and other collaboratorsCompletedJoint Instability | Shoulder DislocationCanada
-
ZygoFixRecruitingLow Back PainGermany, Italy
-
ZygoFixCompletedLow Back PainHungary
-
NEOS SurgeryAnagram-ESICWithdrawn